Literature DB >> 2040175

Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients.

J Bommer1, H P Barth, M Zeier, A Mandelbaum, G Bommer, E Ritz, H Reichel, R Novack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2040175     DOI： 10.1159/000419523

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN： 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  9 in total

Review 1.  Pharmacokinetics/pharmacodynamics of recombinant human erythropoietins in doping control.

Authors:  Emmanuelle Varlet-Marie; Aurélie Gaudard; Michel Audran; Francoise Bressolle
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

Review 2.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

Review 3.  Controversies in determination of epoetin (recombinant human erythropoietin) dosages.

Authors:  P A Abraham; W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites.

Authors:  J D Jensen; L W Jensen; J K Madsen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 5.  Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.

Authors:  C J Dunn; A Markham
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

6.  Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study.

Authors:  Nicholas Kosmadakis; Evangelos Messaris; Antonis Maris; Stylianos Katsaragakis; Emmanouel Leandros; Manoussos M Konstadoulakis; George Androulakis
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

7.  Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia.

Authors:  R E Port; R W Ding; T Fies; K Schärer
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

8.  Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure.

Authors:  A Braun; R Ding; C Seidel; T Fies; A Kurtz; K Schärer
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

9.  Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage.

Authors:  Ruediger E Port; Daniela Kiepe; Michael Van Guilder; Roger W Jelliffe; Otto Mehls
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.